Three more Vivus board members head for the door; Teva launches generic Lovaza in the U.S.;

@FiercePharma: Top-read FiercePharma news Tues.: Express Scripts assembling anti-Sovaldi coalition to shut out Gilead hep C drug. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. News | Follow @TracyStaton

@EricPFierce: FDA is beefing up its inspection staff in China but for now it has 2 drug inspectors in country. More | Follow @EricPFierce

@CarlyHFierce: From FiercePharmaMarketing: Facing a PR crisis? Teva France's chief has some hard-won advice. Article | Follow @CarlyHFierce

> Vivus ($VVUS) directors J. Martin Carroll, Robert Wilson and Mark Logan won't stand for reelection at the company's June 20 annual meeting. 8-K

> Mallinckrodt's ($MNK) $5.6 billion deal to buy Questcor Pharmaceuticals ($QCOR) pushed spending on specialty drugmaker deals in the past year to almost $60 billion, the most for a 12-month period since December 2009. Story

> Teva ($TEVA) has launced a U.S. generic of GlaxoSmithKline's ($GSK) fish oil pill Lovaza. Release

> The European Medicines Agency (EMA) will inspect Ranbaxy's Dewas, India, plant in June. More

Medical Device News

@FierceMedDev: Merck backs microbial Dx outfit as concern about treatment-resistant strains grows. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Deerfield unveils a $1.6B new fund as med tech VC lags. Story | Follow @VarunSaxena2

@EmilyWFierce: New book explores the evolutionary mystery of left-handedness. Article | Follow @EmilyWFierce

@MichaelGFierce: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. More from FierceDrugDelivery | Follow @MichaelGFierce

> InfoBionic brings in $17M to develop its cloud-based patient monitoring system. News

> Boston Scientific takes to Asia with its subcutaneous ICD. More

Biotech News

@FierceBiotech: Novartis, NEA join $188M gamble on China biotech fund. More | Follow @FierceBiotech

@JohnCFierce: After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky. Story | Follow @JohnCFierce

@DamianFierce: This AMA statement on the release of Medicare doctor payments is amazing, via Bloomberg News. Read | Follow @DamianFierce

@EmilyMFierce: In case you missed it here's this week's edition of FierceBiotech Research. Issue | Follow @EmilyMFierce

> 'Special K' once again wows investigators in small depression study. Story

> GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance. News

Drug Delivery News

> Nanoballoons 'pop' open to deliver cancer drugs when hit with a red laser. More

> Novaliq begins clinical trials for SFA-delivered cyclosporin eye drops. Story

> 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Article

> Magnetic nanoparticle hyperthermia with an antibody is effective in breast cancer cells. Report

> AACR: Gold nanorods aim cancer-killing lasers at the bladder. News

> AstraZeneca expands StarPharma deal for cancer drug delivery tech. Item

Diagnostics News

> Maryland Dx startup raises $2.8M to advance cancer genome analysis tech. Item

> Foundation Medicine will develop a test for Clovis' ovarian cancer drug. More

> Roche's Ventana pairs with Genmab on yet another companion Dx deal. Story

> Scripps scientists say new biomarker for various cancers might be more useful. Article

> Adaptive Biotechnologies grabs $105M from a single investor to boost its immune system test. Report

> Ysios is optimistic about diagnostic and device investments in 2014. Editor's corner

> Exact Sciences raises nearly $120M, focused on a hoped-for 2014 launch of its colon cancer Dx. News

> Merck led a $12M round for AdvanDx and its tests for tough hospital infections. More

Pharma Marketing News

> J&J sifts marketing nuggets from Mom's BabyCenter posts. Story

> Facing a PR crisis? Teva France's chief has some hard-won advice. More

> Patients are glued to iPhones and tablets, but pharma ads stick to TV. Article

> Which brands grab the drug-spending title? AbbVie's Humira, AZ's Nexium lead the way. News

> Bayer, J&J beef up Xarelto research to keep market-share gains coming. Report

> Teva puts GSK and Amarin on notice with generic Lovaza launch. Item

And Finally... Motivation to exercise--or lack thereof--may be at least partly inherited. Story (sub. req.)

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.